Primary Outcome Measures Diagnostic Performance Secondary Outcome Measures Location biopsy Staging Patient Management Uptake Values Changes uptake parameters due to anticancer treatment Correlate immunohistochemistry Incidental findings Safety Evaluation FAPI-injection Overall survival Recurrence/Progression Free Survival Response evaluation Interobserver reliability Inclusion Criteria Patients with pleural lesions suspicious of pleural mesothelioma and referred[…]
From the blog
CAR-T Cell Therapy for Mesothelioma
Mesothelioma is a rare and aggressive cancer mainly caused by asbestos exposure. With the disease being rare, there are limited treatment options for the disease. This is especially true for elderly patients. They can struggle with conventional therapies due to their age and health problems. One therapy known as Chimeric[…]
Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE VariaTionS (MAGNETS)
Primary Outcome Measures the comparison of prevalence of germline mutations in MPM patients vs asbestos exposed healthy subjects Secondary Outcome Measures Secondary aim will be the comparison of overall survival (OS) according to mutational status in MPM patients. Inclusion Criteria Inclusion Criteria Cohort A: Patient with a documented diagnosis of[…]
Asbestos Tailings Could be Used to Help the Environment
An abandoned asbestos mine in Baie Verte, in Newfoundland, is expected to have a significant environmental remediation project. BAIE Minerals, a company that specializes in mineral upcycling, plans to transform asbestos into usable resources by utilizing a new, innovative process. The Advocate Mine began operation in 1963, supplying asbestos for[…]
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Primary Outcome Measures Establish the recommended phase 2 dose (RP2D) of TNhYP218 CAR T cells based on dose-limiting toxicity (DLT) of defined adverse events (AEs). Determine the preliminary objective response rate of TNhYP218 CAR T cells in a limited number of participants with mesothelioma treated at the recommended phase 2[…]
Surgeries for Mesothelioma
Pleural mesothelioma is a very rare and aggressive cancer mainly caused by asbestos exposure. The survival time is very low, with people typically surviving around 9 to 20 months after treatment starts. The overall survival rate is around five percent, which means only five percent of people still live after[…]
Blood Biomarkers for Mesothelioma
A mesothelioma diagnosis is hard to receive and can be very overwhelming. Different research outcomes can help doctors and patients make better decisions though. One area of research is blood-based biomarkers. Two biomarkers that can help monitor mesothelioma include mesothelin-related protein (SMRP) and cancer antigen 125 (CA-125). They help monitor[…]
Chrysotile Asbestos Carcinogenesis
Mesothelioma, a tough to treat and severe cancer mainly caused by asbestos, continues to be a global health and safety issue. Chrysotile, the most abundant form of asbestos, is especially harmful due to how prevalent it is. Researchers looked at chrysotile and the heat-treated form forsterite to find the best[…]
Improving Mesothelioma Diagnosis
Malignant mesothelioma, an aggressive cancer mainly caused by asbestos, mainly affects the pleura, the lining of the lungs. It also affects the peritoneum, which is the lining of the abdomen. It is very tough to diagnose mesothelioma, which leads to underdiagnosis of the disease. A study in Brazil’s Sao Paulo[…]
Evaluating Ivonescimab As a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy (Bi-MAPS)
Primary Outcome Measures The analysis of the primary efficacy endpoint will be conducted in all eligible patients, based on the disease control rate (DCR) at 12 weeks according to mRECIST 1.1 for mesothelioma, which was defined as the proportion of patients with compete response (CR), partial response (PR) or stable[…]
